J U LY 2 4 , 2 0 1 8

•
•

• •

• •
• •
•
• •

•
•

•
•

•
•

•
•
• •

• •

• •

•
•

• •
•
•
•
•
•
 MIRIKIZUMAB LEGEND
Ulcerative Colitis
NEW CHEMICAL ENTITY
AUR A KIN INH PDE4 INHIBITOR BARICITINIB DULAGLUTIDE
Cancer Immunology Atopic Dermatitis 3.0 / 4.5 mg
NEW BIOTECH ENTITY
SEL BACE 1 INH ERK INHIBITOR EMPAGLIFLOZIN* EMPAGLIFLOZIN*
Alzheimer’s Cancer Type 1 Diabetes Heart Failure NILEX

Commercial Collaboration
IDO1 INHIBITOR
Cancer
DACRA-089
Diabetes
PEGILODECAKIN
NSCLC
GALCANEZUMAB
Cluster Headache
TANEZUMAB*
Chronic Lower Back Pain
*
BAFF/IL-17 IL-23/CGRP MIRIKIZUMAB ABEMACICLIB TANEZUMAB* ABEMACICLIB MOVEMENT SINCE
Immunology Immunology Crohn’s Disease HR+/HER2+MBC Cancer Pain Adjuvant Breast Cancer
APRIL 20, 2018
Ab42 MAB IL-2 PEG TGFb R1 KI BARICITINIB, Systemic RAMUCIRUMAB RAMUCIRUMAB, 2nd Line
Alzheimer’s Immunology Cancer Lupus Erythematosus 2nd Line Bladder Cancer Hepatocellular Cancer ACHIEVED MILESTONE

AUTO INSULIN DELIVERY IL-33 MAB PREXASERTIB D1 PAM RAMUCIRUMAB IXEKIZUMAB REMOVAL
SYSTEM Diabetes Immunology Cancer Dementia 1st Line NSCLC Non-Radiographic AxSpA

BASAL INSULIN-FC TIM-3 MAB PI3/MTOR INH MERESTINIB LASMIDITAN IXEKIZUMAB

Diabetes Cancer Cancer Cancer Migraine Radiographic AxSpA

IL-21 MAB OXYNTOMODULIN N3PG + BACE COMBO BTK INHIBITOR PEGILODECAKIN FLORTAUCIPIR
Immunology Diabetes Alzheimer’s Immunology Pancreatic Cancer Tau Imaging, diagnostic

PD-L1 + LY COMBO CXCR1/2L MAB TAU DEPOSIT MAB GIP/GLP-1 MIRIKIZUMAB TANEZUMAB*
Cancer Immunology Alzheimer’s Diabetes Psoriasis Osteoarthritis Pain

HYPOGLYCEMIA CSF1R MAB DACRA-042 N3PG Ab MAB SOLANEZUMAB ULTRA-RAPID LISPRO NASAL GLUCAGON GALCANEZUMAB
Diabetes Cancer Diabetes Alzheimer’s Preclinical AD Diabetes Hypoglycemia Migraine

PHASE 1 PHASE 2 PHASE 3 R E G U L AT O RY R E V I E W

GPR142 AGONIST LANABECESTAT*

Diabetes Alzheimer’s
 
  


 
 


 




 •
•
•

• • • •

• •

•
•

•
•

•
•

•
•

•
•